We are live on ! Find out more
PTGX icon

Protagonist Therapeutics
PTGX

66 hedge funds and large institutions have $208M invested in Protagonist Therapeutics in 2019 Q2 according to their latest regulatory filings, with 15 funds opening new positions, 30 increasing their positions, 16 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

88% more repeat investments, than reductions

Existing positions increased: 30 | Existing positions reduced: 16

15% more first-time investments, than exits

New positions opened: 15 | Existing positions closed: 13

10% more capital invested

Capital invested by funds: $189M → $208M (+$19.2M)

9.09% more ownership

Funds ownership: 64.51% → 73.6% (+9.1%)

3% more funds holding

Funds holding: 64 → 66 (+2)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

Holders
66
Holders Change
+2
Holders Change %
+3.13%
% of All Funds
1.43%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
15
Increased
30
Reduced
16
Closed
13
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$8.22M
2
BBA
Baker Bros. Advisors
New York
+$6.54M
3
ACP
Acuta Capital Partners
California
+$3.69M
4
JP Morgan Chase
JP Morgan Chase
New York
+$3.07M
5
VMI
VHCP Management III
New York
+$2.91M

Top Sellers

Rank Fund Capital Flow
1
GTC
Ghost Tree Capital
New York
-$5.53M
2
FCM
Farallon Capital Management
California
-$3.21M
3
Acadian Asset Management
Acadian Asset Management
Massachusetts
-$3.05M
4
WCM
Wedge Capital Management
North Carolina
-$1.7M
5
Fidelity Investments
Fidelity Investments
Massachusetts
-$1.08M
Name Holding Trade Value Shares
Change 		Change in
Stake
Bank of New York Mellon
26
Bank of New York Mellon
New York
$1.26M +$454K +41,052 +65%
Squarepoint
27
Squarepoint
New York
$1.24M +$636K +57,560 +129%
SSA
28
Schonfeld Strategic Advisors
New York
$1.23M +$860K +77,800 +324%
BCM
29
Bridgeway Capital Management
Texas
$1.1M -$334K -30,256 -25%
Invesco
30
Invesco
Georgia
$1.03M +$150K +13,536 +19%
WAM
31
Wolverine Asset Management
Illinois
$968K +$884K +80,000 New
Northern Trust
32
Northern Trust
Illinois
$851K +$348K +31,477 +81%
FI
33
Fosun International
China
$569K – – –
Deutsche Bank
34
Deutsche Bank
Germany
$548K +$147K +13,333 +42%
N
35
Nuveen
North Carolina
$470K +$430K +38,875 New
Charles Schwab
36
Charles Schwab
California
$442K +$403K +36,469 New
Barclays
37
Barclays
United Kingdom
$302K -$438K -39,594 -61%
Goldman Sachs
38
Goldman Sachs
New York
$291K -$851K -76,931 -76%
NHAS
39
Novo Holdings A/S
Denmark
$289K +$264K +23,901 New
FSA
40
Franklin Street Advisors
North Carolina
$285K – – –
California State Teachers Retirement System (CalSTRS)
41
California State Teachers Retirement System (CalSTRS)
California
$283K +$258K +23,347 New
Wells Fargo
42
Wells Fargo
California
$248K +$46.7K +4,224 +26%
FIM
43
Freedom Investment Management
Connecticut
$245K -$3.92K -355 -2%
T. Rowe Price Associates
44
T. Rowe Price Associates
Maryland
$236K +$83.9K +7,586 +64%
Marshall Wace
45
Marshall Wace
United Kingdom
$216K +$197K +17,799 New
PPA
46
Parametric Portfolio Associates
Washington
$209K +$1.17K +106 +0.6%
KWMG
47
King Wealth Management Group
Florida
$206K -$27.6K -2,500 -13%
AG
48
Algert Global
California
$188K +$55.6K +5,030 +48%
New York State Common Retirement Fund
49
New York State Common Retirement Fund
New York
$188K +$171K +15,500 New
PP
50
PDT Partners
New York
$182K +$166K +15,011 New
1
2
3 4

PTGX Hedge Fund Activity: Q2 2019 in Review

66 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in Protagonist Therapeutics (PTGX) for Q2 2019, worth a combined $208M — up 10% from $189M a quarter earlier.

Buyers outnumbered sellers: 15 funds opened new PTGX positions and 13 closed out — a net gain of 2 holders — while 30 added to existing stakes and 16 trimmed.

The largest buyer was BlackRock, adding an estimated $8.22M. The largest seller was Ghost Tree Capital, cutting an estimated $5.53M.

  • 66 institutional investors held Protagonist Therapeutics (PTGX) as of Q2 2019, up from 64 in Q1 2019.
  • Funds reported $208M of Protagonist Therapeutics stock for Q2 2019, up 10% quarter-over-quarter.
  • 15 funds opened new Protagonist Therapeutics positions in Q2 2019 and 13 closed out, a net change of +2 holders.
  • The largest Protagonist Therapeutics buyer in Q2 2019 was BlackRock, an estimated $8.22M added.
  • The largest Protagonist Therapeutics seller in Q2 2019 was Ghost Tree Capital, an estimated $5.53M sold.

Based on aggregated 13F filings for Q2 2019.